Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385382 | 0.92 | CTSK (0.44) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL13044371 | 0.92 | CTSK (0.44) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL16020434 | 0.90 | CYP1A2 (0.44) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL19236423 | 0.89 | CYP1A2 (0.58) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1088542 | 0.88 | PPARA (0.51) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1100322 | 0.88 | PPARA (0.51) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL29915508 | 0.85 | TSHR (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1867256 | 0.85 | CTSS (0.44) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL13044365 | 0.85 | CYP1A2 (0.45) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL34465210 | 0.85 | CYP1A2 (0.42) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901353-B2 | Polyimide precursor, polyimide, and liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | PUF60, F13A1, F12 | CTSK 4427/4885CTSS 4745/4885CTSL 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.